These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 84653)

  • 1. Comparison between the effects of Micrococcus, BCG and related polysaccharides in preclinical chemo-immunotherapy of murine L 1210 leukaemia [proceedings].
    Verloes R; Atassi G; Dumont P; Kanarek L
    Arch Int Physiol Biochim; 1978 Oct; 86(4):969-71. PubMed ID: 84653
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of Micrococcus, BCG and related polysaccharides in the specific and non-specific immune resistance to murine L1210 leukemia [proceedings].
    Verloes R; Atassi G; Dumont P; Kanarek L
    Arch Int Physiol Biochim; 1978 May; 86(2):466-8. PubMed ID: 81034
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful immunotherapy with micrococcus, BCG or related polysaccharides on L1210 leukaemia after BCNU chemotherapy.
    Verloes R; Atassi G; Dumont P; Kanarek L
    Br J Cancer; 1981 Feb; 43(2):201-9. PubMed ID: 7470382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superiority of Micrococcus lysodeikticus to BCG in chemo-immunotherapy of advanced L1210 leukaemia.
    Verloes R; Atassi G
    Eur J Cancer Clin Oncol; 1981 Aug; 17(8):849-56. PubMed ID: 6799298
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of micrococcus, BCG and related polysaccharides on the proliferation of the L1210 leukaemia.
    Verloes R; Atassi G; Dumont P; Kanarek L
    Br J Cancer; 1978 Nov; 38(5):599-605. PubMed ID: 728349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCG in cancer immunotherapy: experimental and clinical trials of its use in treatment of leukemia minimal and or residual disease.
    Mathé G; Weiner R; Pouillart P; Schwarzenberg L; Jasmin C; Schneider M; Hayat M; Amiel JL; de Vassal F; Rosenfeld C
    Natl Cancer Inst Monogr; 1973 Dec; 39():165-75. PubMed ID: 4595314
    [No Abstract]   [Full Text] [Related]  

  • 7. Active immunotherapy in spontaneous leukemia of AkR mice.
    Mathé G; Halle-Pannenko O; Bourut C
    Exp Hematol; 1973; 1(2):110-4. PubMed ID: 4609352
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immune manipulation of BCG administered before or after cyclophosphamide for chemo-immunotherapy of L1210 leukemia].
    Mathé G; Halle-Pannenko O; Bourut C
    C R Acad Hebd Seances Acad Sci D; 1975 Apr; 280(13):1623-6. PubMed ID: 811377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer.
    Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ
    Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074
    [No Abstract]   [Full Text] [Related]  

  • 10. BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy.
    Mathé G; Halle-Pannenko O; Bourut C
    Natl Cancer Inst Monogr; 1973 Dec; 39():107-13. PubMed ID: 4150738
    [No Abstract]   [Full Text] [Related]  

  • 11. Methanol extraction residue fraction of tubercle bacilli (MER) and other mycobacterial extracts as systemic immunity adjuvants in cancer immunotherapy.
    Mathé G; Hiu IJ; Halle-Pannenko O; Bourut C
    Isr J Med Sci; 1976; 12(4-5):468-71. PubMed ID: 820673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The second generation of EORTC-ECIG experimental screening for systemic immunity adjuvants. Its significance for cancer immunotherapy. A comparison of BCG and its hydrosoluble extract.
    Mathe G; Halle-Pannenko O; Florentin I; Bruley-Rosset M; Kamel M; Hiu IJ; Bourut C
    Eur J Cancer (1965); 1975 Nov; 11(11):801-7. PubMed ID: 767112
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute myelocytic leukemia.
    Holland JF; Glidewell O; Ellison RR; Corey RW; Schwartz J; Wallace HJ; Hoagland HC; Wiernik P; Rai K; Bekesi JG; Cuttner J
    Arch Intern Med; 1976 Dec; 136(12):1377-81. PubMed ID: 793552
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotherapy of leukaemia.
    Malpas JS
    Schweiz Med Wochenschr; 1974 May; 104(18):626-33. PubMed ID: 4596725
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the in vivo multiplication of 10 BCG substrains in three strains of mice: no correlation with their antitumour activity.
    Frenette M; Portelance V; Beaudet R
    Microbios; 1983; 36(145-46):173-82. PubMed ID: 6346021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between humoral immunity and successful chemotherapy-immunotherapy.
    Cantrell JL; Killion JJ; Kollmorgen GM
    Cancer Res; 1976 Sep; 36(9 pt.1):3051-7. PubMed ID: 788896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter: Routes other than I.V. injection to mice for BCG administration in active immunotherapy of L1210 leukemia.
    Martin M; Bourut C; Halle-Pannenko O; Mathé
    Biomedicine; 1975 Oct; 23(8):339-40. PubMed ID: 1231929
    [No Abstract]   [Full Text] [Related]  

  • 18. [Active immunotherapy of L 1210 leukemia given after the graft of the tumor].
    Mathé G
    Rev Fr Etud Clin Biol; 1968 Nov; 13(9):881-3. PubMed ID: 5304470
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune manipulation by BCG administered before or after cyclophosphamide for chemo-immunotherapy of L1210 leukaemia.
    Mathé G; Halle-Pannenko O; Bourut C
    Eur J Cancer (1965); 1974 Oct; 10(10):661-6. PubMed ID: 4465103
    [No Abstract]   [Full Text] [Related]  

  • 20. Active immunotherapy in the treatment of experimental leukemias and acute lymphoblastic leukemia in man.
    Mathé G; Hayat M; Amiel JL; Schwarzenberg L; Schneider M; Pouillart P; Cattan A
    Boll Ist Sieroter Milan; 1971; 50(4):251-9. PubMed ID: 5293498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.